AI-based radiotherapy planning for cervical, head and neck, and prostate cancer
ARCHERY - Artificial Intelligence Based Radiotherapy Treatment Planning for Cervical, Head and Neck and Prostate Cancer
This study is testing whether an AI program can make radiotherapy for cervical, head and neck, and prostate cancer faster and more accurate for patients.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 990 (estimated) |
| Ages | 18 Years and up |
| Sex | All |
| Sponsor | University College, London Academic / other |
| Drugs / interventions | radiation |
| Locations | 6 sites (Kolkata and 5 other locations) |
| Trial ID | NCT05653063 on ClinicalTrials.gov |
What this trial studies
This study aims to evaluate the effectiveness of an artificial intelligence (AI) program designed to automate key components of the radiotherapy treatment process for patients with cervical, head and neck, and prostate cancers. The AI tool focuses on accurately delineating anatomical areas at risk of tumor spread and defining the radiation beam's position, size, and shape. By streamlining these tasks, the study seeks to enhance treatment accuracy and significantly reduce the time and resources required for radiotherapy. The ultimate goal is to determine if this AI-based approach can be integrated into routine clinical practice.
Who should consider this trial
Good fit: Ideal candidates include adults aged 18 and older with histologically confirmed cervical, head and neck, or prostate cancers who are eligible for radical radiotherapy.
Not a fit: Patients requiring radiotherapy after curative surgery or those receiving palliative radiotherapy may not benefit from this study.
Why it matters
Potential benefit: If successful, this study could lead to more accurate and efficient radiotherapy treatments for cancer patients.
How similar studies have performed: Other studies have shown promise in using AI for radiotherapy planning, indicating a growing interest and potential in this innovative approach.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: 1. Consecutive patients with histologically confirmed head and neck cancers of the oropharynx, larynx, hypopharynx and nasopharynx (Stage I-III) that have given consent for radical radiotherapy. 2. Consecutive histologically confirmed primary cervical cancer patients (Stage IB-IIIB including pelvic node positive) that have given consent for radical radiotherapy. 3. Consecutive histologically confirmed primary prostate cancer patients (T1-4N0M0) that have given consent for radical radiotherapy. 4. Mental capacity to understand and consent to participate in the study. 5. Patients aged ≥18years. Exclusion Criteria: 1. Patients requiring radiotherapy after curative surgery or surgery that is intended to remove as much of the tumour as possible. 2. Patients receiving palliative radiotherapy 3. Patients aged \< 18years.
Where this trial is running
Kolkata and 5 other locations
- Tata Medical Centre — Kolkata, India (Recruiting)
- Tata Memorial Hospital — Mumbai, India (Recruiting)
- King Hussein Cancer Center — Amman, Jordan (Recruiting)
- University of Malaya Medical Center — Kuala Lumpur, Malaysia (Recruiting)
- Groote Schuur Hospital — Cape Town, South Africa (Recruiting)
- Tygerberg Hospital — Stellenbosch, South Africa (Not_yet_recruiting)
Study contacts
- Study coordinator: ARCHERY Trial Manager
- Email: mrcctu.archery@ucl.ac.uk
- Phone: +442076704637
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.